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Kv7 channels, especially Kv7.2 (KCNQ2) and Kv7.3 (KCNQ3),
are key determinants formembrane excitability in the brain. Some
chemical modulators of KCNQ channels are in development for
use as anti-epileptic drugs, such as retigabine (D-23129, N-(2-
amino-4-(4-fluorobenzylamino)-phenyl)), which was recently
approved for clinical use. In addition, several other compounds
were also reported to potentiate activity of the Kv7 channels. It is
therefore of interest to investigate compound-channel interac-
tions, so that more insights may be gained to aid future develop-
ment of therapeutics.We have conducted a screen of 20,000 com-
pounds for KCNQ2 potentiators using rubidium flux combined
with atomic absorption spectrometry. Here, we report the charac-
terization of a series of new structures that display isoform speci-
ficity and induce amarked reduction of deactivation distinct from
that of retigabine. Furthermore, KCNQ2(W236L), a previously
reportedmutation that abolishes sensitivity to retigabine, remains
fully sensitive to these compounds. This result, together with
mutagenesis and other studies, suggests that the reported com-
pounds confer a uniquemode of action and involve newmolecular
determinants on the channel protein, consistent with the idea of
recognizing a new site on channel protein.
Potassium channels represent a major group of drug targets
critical for clinical treatment for a variety of diseases (1). Exten-
sive biophysical studies of potassium channels in both native
and recombinant systems have led to the appreciation that the
close-open transition of a given channel may be influenced by
both physical and chemical factors (2–4). For example, the large
conductance, calcium-gated potassium channel (BK), which is
normally activated by a combination ofmembrane depolarization
and elevated intracellular calcium, may be activated by high con-
centrations of calcium alone, at the resting potential, without
depolarization (5, 6). Among the Kv channels, voltage-gating
appears to be “dominant,” and few channels could be gated by
ligands in the absence of membrane depolarization.
Neuronal Kv7 (or KCNQ) channels are activated at sub-
threshold membrane potentials. Because activation of these
channels could dampenmembrane excitability, potentiation of
these channels by synthetic chemical ligands is believed to be
beneficial in treating diseases with hyperexcitibility, such as
epilepsy and neuropathic pains (7, 8). Conversely, loss-of-func-
tion mutations in these channels lead to benign familial neona-
tal convulsion syndrome (9). Drug-induced potentiation of
channel activity (i.e. increase of net current flow in a given time
period) may be achieved by several mechanisms, including
modulation of protein expression, channel gating, or single
channel conductance. A number of compounds have been
reported to display potentiating activities on KCNQ channels
(e.g. see a recent review (10)). For example, potent anti-epileptic
activities were reported for ICA-27243 in various rodent con-
vulsant models (e.g. ED50 values were 1.5 and 2.2 mg/kg per
oral for maximal electroshock- and pentylenetetrazole-in-
duced seizure models in rats, respectively) (11–14). How-
ever, for most of these compounds, limited structure-activity
relationship (SAR)6 data are available.
KCNQ channels are widely expressed in different tissues
(15). There are five isoforms with more than 40% amino acid
identity within the six-transmembrane segment core regions.
Although the atomic structure of Kv7 channels is not yet avail-
able, structures of homologousKv channels, such asKv1.2, have
been used to model the structures of Kv7 channels (16). Earlier
evidence suggests that KCNQ2 to KCNQ5 are neuronal iso-
forms (17–20), whereas KCNQ1 is a non-neuronal isoform,
found primarily in cardiac myocytes mediating IKs (slow
delayed rectifies potassium current) current upon coassembly
with non-conductive accessory KCNE1 subunits (17, 21, 22).
NeuronalMcurrents are thought tobemediatedby coassemblyof
KCNQ2withKCNQ3and to a lesser extentwithKCNQ4 (17, 23).
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Supplemental Material can be found at:
Recent evidence suggests that KCNQ2 homomultimers could be
responsible for theMcurrent incertainregionsof thecentralnerv-
ous system (24). Thus, isoform-specific KCNQ activators would
be important tools for exploring thecompositionandpropertiesof
M currents in native tissues.
Assays to monitor potassium channel activity can be broadly
divided into three classes: conventional binding assays, flux-
based assays, and electrophysiological recordings (25). Consid-
ering throughput and correlation with channel activity, flux
assays have been more commonly used in high throughput
screens (25, 26). Rubidium (Rb) and thallium (Tl) are two
surrogate, heavy metal ions that permeate throughmost potas-
sium channels. Because they are non-physiological ions, they
allow improved signal-to-noise ratios in flux assays (27, 28).
In an effort to examine the chemical repertoire of KCNQ
activators, we screened a collection of 20,000 compounds
against KCNQ2 homomeric channels and identified multiple
series of structures with distinct chemotypes. It is of impor-
tance both to characterize their regulatory attributes and to
define active chemical groups. Here, we report an SAR study,
which shows diverse effects of highly similar structures display-
ing profound differences in potentiating KCNQ homomulti-
meric channels.We also identify critical residues for the poten-
tiating activities of these compounds, providing supportive
evidence of a new binding site.
EXPERIMENTAL PROCEDURES
cDNAs andMutagenesis
The KCNQ1–KCNQ5 cDNAs were gifts from Drs. T.
Jentsch (Zentrum fu¨r Molekulare Neurobiologie, Hamburg), D.
Makinnon (State University of New York, Stony Brook), M. San-
guinetti (University of Utah), M. Shapiro (University of Texas
Health Science Center, San Antonio), and V. Vardanyan (Univer-
sita¨t Hamburg), respectively. Pointmutations were introduced by
using theQuikChange II site-directedmutagenesiskit (Stratagene,
La Jolla, CA) and verified by DNA sequencing.
Cell Culture and Transfection
Chinese hamster ovary (CHO) cells were grown in 50/50
DMEM/F-12 (Cellgro, Manassas, VA) with 10% fetal bovine
serum (FBS), and 2 mM L-glutamine (Invitrogen). To express
KCNQchannels andmutants, cells were split at 24 h before trans-
fection, plated in 60-mm dishes, and transfected with Lipo-
fectamine 2000TM reagent (Invitrogen), according to the manu-
facturer’s instructions. At 24 h after transfection, cells were split
and replated onto coverslips coated with poly-L-lysine (Sigma). A
GFP cDNA (Amaxa, Gaithersburg, MD) was cotransfected to
identify the transfected cells by fluorescencemicroscopy.
High Throughput Library Screening and Hits Validation using
the Rb Flux Assay
A screen of the ChemBridge DiversetTM library of 20,000
compounds for KCNQ2 channel modulators was performed
using a Rb flux assay reported earlier (29, 30). To validate the
hits from the initial screen, compounds were cherry-picked
from the original compound library and retested using the Rb
efflux assay using wild type KCNQ2. To test whether the acti-
vator hits have similar effects on KCNQ2W236Lmutant chan-
nels, a Rb flux assay was performed using a CHO KCNQ2
W236L stable cell line with the same assay format. Hits were
selected with the same criteria (increase or decrease of the Rb
flux level by 3 times the S.D. comparedwith theDMSOcontrol)
for each assay format.
High Throughput Library Screening Using the Tl Flux Assay
For screening the focused compound library, the Tl BTC
flux assay was performed according to the published protocol
(28) with modifications. Briefly, freshly cultured HEK293 cells
stably expressing KCNQ2 channels were seeded onto poly-D-
lysine-coated, 384-well BectonDickinson plates by aMultidrop
dispenser and incubated overnight at 37 °C in a 5% CO2 incu-
bator. After manual removal of themedium, BTC-AM solution
(2M, 50l) was added into the cell plates and incubated in the
dark, at room temperature, for 60min. Then theBTC-AMsolu-
tion was manually removed, and cell plates were washed twice
with chloride-free buffer and loaded with 25 l/well of chlo-
ride-free buffer. The compound plates were prepared in chlo-
ride-free buffer with Tl stimulus solution; the final concentra-
tion of Tl in the assay wells was 7.5 mM, and the compound
concentrations were 20 or 2M upon the addition of 25l/well
from compound plates. Both compound plates and cell plates
were mounted on the FDSS (Hamamatsu Photonics Ltd.,
Japan), and cell plates were prereadwith excitation at 480 nmand
emission at 540 nm for 5 s, at a 1-Hz frequency, before the com-
pounds were added into the cell plates. The fluorescence
responses from cell plates were continuously monitored for 100 s
at a 1-Hz frequency. The ratios of fluorescence (F/F0) were cor-
rected for background autofluorescence and were used for quan-
tification of KCNQ2 channel responses to the compound library.
Retigabine (10M) and/or zincpyrithione (ZnPy; 10M) served as
positive controls.Negative controlswere buffer solutions contain-
ingDMSOat the sameconcentrationsusedwithcompoundappli-
cation. The assay displayed a good Z factor (0.5) and signal-to-
noise ratio (7).
Electrophysiological Recording in CHO Cells
Whole cell voltage clamp recording was carried out, using
cultured CHO cells, at room temperature, with an Axopatch-
200B amplifier (Molecular Devices, Sunnyvale, CA). The elec-
trodes were pulled from borosilicate glass capillaries (World
Precision Instruments, Sarasota, FL). When filled with the
intracellular solution, the electrodes had resistances of 3–5
megaohms. Pipette solution contained 145 mM KCl, 1 mM
MgCl2, 5mMEGTA, 10mMHEPES, 5mMMgATP (pH 7.3 with
KOH). During the recording, constant perfusion of extracellu-
lar solutionwasmaintained using a BPS perfusion system (ALA
Scientific Instruments, Westburg, NY). Extracellular solution
contained 140mMNaCl, 5mMKCl, 2mMCaCl2, 1.5mMMgCl2,
10 mM HEPES, 10 mM glucose (pH 7.4 with NaOH). Signals
were filtered at 1 kHz and digitized using a DigiData 1322A,
with pClamp 9.2 software (Molecular Devices, Sunnyvale, CA).
Series resistance was compensated by 60–80%. In the present
study, various voltage protocols were used. The holding poten-
tial was 120 mV in all voltage protocols, except where indi-
cated. To elicit the currents, cells were stimulated by a series of
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2,000-ms depolarizing steps, from 80 mV to 50 mV, in
10-mV increments.
Chemical Synthesis
Chemical synthesis was proceeded as shown in Reaction 1.
REACTION 1
General Methods—Dicyclohexylcarbodiimide (DCC) was
added and stirred for 30min into a solution of carboxylic acid 1
(0.36 mmol) in tetrahydrofuran (THF) (2 ml) at 0 °C. Then
amine 2 (0.3 mmol) was added to the mixture, followed by the
addition of dimethyl aminopyridine (DMAP; 0.06 mmol). The
reactionmixture was allowed to stir at room temperature over-
night. After evaporating the volatiles, the mixture was parti-
tioned by CH2Cl2 (2 20 ml) and saturated NaHCO3 solution
(20 ml), dried over anhydrous Na2SO4, and concentrated in
vacuo. The residue was purified by column chromatography to
give the desired amide ztz series compounds as described (see
supplemental material). The other analogues were synthesized
in a similar manner.
ztz240 Preparation and Characterization—ztz240 was pre-
pared using the general procedure in 85% yield. The character-
ization of the ztz240 series of compounds was examined by 1H
and 13C NMR and high resolution
mass spectrometry. These spectra
show high purity (95%) of these
compounds. For ztz240, 1H NMR
(CDCl3  CD3OD, 500 MHz):  
8.42 (d, J  2.5 Hz, 1H), 8.41–8.26
(m, 1H), 7.91–7.88 (m, 2H), 7.27 (d,
J  8.5 Hz, 1H), 7.11–7.07 (m, 2H);
13C NMR (CDCl3  CD3OD, 125
MHz):   166.1, 145.6, 141.4,
141.3, 134.9, 131.2, 130.3 2, 130.1,
124.4, 115.9  2. Detailed prepara-
tion procedure and purity informa-
tion of other derivatives are avail-
able (see supplemental material).
Data and Statistical Analysis
Patch clamp data were processed
using Clampfit 9.2 (Molecular
Devices, Sunnyvale, CA) and then
analyzed in GraphPad Prism 4
(GraphPad Software, San Diego,
CA). Voltage-dependent activation
curves were fitted with the Boltz-
mann equation, G  Gmin 
(Gmax  Gmin)/(1  exp(V  V1⁄2)/
S)), where Gmax is the maximum
conductance, Gmin is the minimum
conductance, V1⁄2 is the voltage for
reaching 50% of maximum con-
ductance, and S is the slope factor. Dose-response curves
were fitted with the Hill equation, E  Emax/
(1 (EC50/C)P), where EC50 is the drug concentration produc-
ing half of the maximum response, and P is the Hill coefficient.
The activation and deactivation traces were fitted with expo-
nential equations containing one or two components using
Clampfit 9.2. Data are presented as means  S.E. Significance
was estimated using paired two-tailed Student’s t tests.
RESULTS
Identification of ztz240 as anActivator for KCNQ2—To iden-
tify compounds with potentiator activities for M currents, we
generated stable cell lines for both KCNQ2 and KCNQ2/3.
After a series of optimizations for several key high throughput
screening parameters, a standard procedure of Rb flux assay
was developed and used to screen a ChemBridge DiversetTM
library of 20,000 compounds at a 10 M final concentration
(31). In this pilot screen against KCNQ2 homomeric chan-
nels, we selected 670 hits, including both potentiators and
inhibitors. Among the 270 potentiator hits, 92 have been
validated with more than 15% increase in signal intensity
(3  S.D., with Z  0.62). To increase the probability of
finding new and interesting structures with novel modes of
action, we applied a triage criterion by examining the com-
pound effects on KCNQ2(W236L), a mutation that abolishes
sensitivity to retigabine, a well known KCNQ potentiator
(32, 33). In addition to ZnPy, reported earlier (31), we have
also found several other compound classes effective on
FIGURE 1. Structures of primary screen hits and derivatives. A, a series of initial hits identified from the
ChemBridge Diverset compound collection, with ChemBridge ID number as indicated. B, derivatives of nitro-
gen position and ring placements (X, Y F, Cl, Br; n 0, 1, 2). C, structures of ztz240 and ICA-27243 (ztz233; see
Figs. 8 and 9).
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KCNQ2(W236L)(Fig. 1A). We further tested 5337031,
which potentiated KCNQ2 channel activities in a dose-de-
pendent manner, with an EC50 value of 9.8  0.2 M.
We have pursued conventional chemical synthesis in an
effort to both validate and evaluate efficacy and pharmacology
of these compounds. Based on the inspection of several active
structures from the primary screen (Fig. 1A), it appears that two
aromatic moieties, linked via an amide bridge, play critical
pharmacological roles in activation of KCNQ channels. These
structures displayed considerable similarity to an ICAgen com-
pound, ICA-27243 (Fig. 1C) (11–14). To explore this notion, we
first examined a series of analogues with different nitrogen
positions. Fig. 1B outlined the four classes of chemical scaffolds
selected to incorporate additional modifications of positions 1
and 2, using a positional scanning approach. The number of
compounds to be synthesized for testing is guided by the “Top-
liss scheme.” The Topliss scheme is
an efficient strategy for identifying
the optimum substitution on the
benzene ring in an active lead com-
pound for maximization of com-
pound potency and minimizing the
number of compounds to be synthe-
sized by incorporation of hydropho-
bic, electronic, and steric effects (34,
35).
ztz240 (N-(6-chloro-pyridin-3-
yl)-4-fluorobenzamide) was one of
the initial 52 derivatives made (Fig.
1C and supplemental material). Fig.
2 shows KCNQ2 currents in tran-
siently transfected cells elicited by
depolarization steps from a holding
potential of 80 mV, as described
earlier (31). The depolarization
steps slowly activated a series of
non-inactivating outward potas-
sium currents (Fig. 2A). In the
absence of drug, the 800-ms dura-
tion of hyperpolarization step to
120 mV completely deactivated
the channel, with a time constant of
20.6  3.4 ms (n  6). In the pres-
ence of 10 M ztz240, we observed
a significant increase in outward
current amplitude, accompanied
by considerable prolongation of
inward current during the repolar-
ization period at 120 mV, indic-
ative of slowing in deactivation
kinetics.
To examine the effect more
closely, the holding potential was
shifted to a more negative value of
120 mV that removes the initial,
instantaneous current upon depo-
larization.With themodified proto-
col, the outward current potentia-
tion was still observed. The channel closed slowly, taking10 s
at 120 mV. The voltage activation curve reveals that ztz240
dramatically left-shifted the V1⁄2 by more than 45 mV, from
11.4 4.2 mV to58.7 7.7 mV (n 4, p	 0.05) (Fig. 2D),
consistent with the observation that10% of the channels are
in the open state, at 80 mV, in the presence of ztz240. The
potentiation of outward current was dose-dependent, with a
half-maximal value (EC50) of 5.8 0.9 M and a 2.2 0.3-fold
potentiation of current at maximal doses (n 6) (Fig. 2C).
In comparison with effects by other activators, such as reti-
gabine (32–33, 36) and ZnPy (31), ztz240 shows different
effects, most noticeably on slowing channel deactivation. Nor-
mally, the deactivation of KCNQ2 channel could be fitted by a
single exponential function, which was increased from 14.6 
1.3 to 27.2 2.6 ms (n 4) by retigabine or to 64.9 12.6 ms
by ZnPy (n 5) (Fig. 3A) (31, 36). In contrast, ztz240 dramati-
FIGURE 2. ztz240 activation on KCNQ2 channels. A, the representative traces of KCNQ2, before and after
application of 10M ztz240, elicited by the protocol as indicated. The holdingpotential is80mV, followedby
a series of depolarization steps from70 to50mV in 10-mV increments, followed by an 800-ms hypopolar-
ization step to120 mV to record the tail current. B, the representative traces of KCNQ2, with and without 10
M ztz240, elicited by a modified protocol from A, as indicated. The holding potential was120 mV. C, dose-
response curve of ztz240 effects on outward current of KCNQ2 channels. The ratio of outward current ampli-
tude in the presence of the compound (I) versus that in the absence of compound (I0) was plotted against
compound concentration. The outward currents were elicited by a 2-s depolarization to 50 mV from the
holdingpotential,120mV.D, voltageactivation curvesof KCNQ2, in theabsenceorpresenceof 10Mztz240.
Error bars, S.E.
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cally prolonged deactivation, which was better fitted by a biex-
ponential function,with fast and slow time constants of 171.9
62.5 ms and 3,230.5 534.1 ms (n 6), respectively (Fig. 3B).
We then studied the effects of ztz240 on deactivation at dif-
ferent voltages. Currents were elicited by depolarization to50
mV, followed by hyperpolarization to different testing voltages
from 100 to 140 mV (Fig. 3C). The deactivation rate was
plotted against voltages in the absence (Fig. 3D) or presence
(Fig. 3E) of ztz240. The slow time constant (s) at120mVwas
plotted against the ztz240 concentration (Fig. 3H) and revealed
an EC50 value of 5.9  0.5 M (n  6), which is essentially
identical to the EC50 obtained from the increased conductance
(Fig. 2C). The activation phase could be fitted by a biexponen-
tial function, and ztz240 displayed only modest effects (Fig. 3, F
and G). In contrast, retigabine greatly accelerated the KCNQ
activation rate (31, 36)(Fig. 3A).
Molecular Specificity and Critical Residues for ztz240 Modula-
tion—The KCNQ family includes five members, termed as
KCNQ1–KCNQ5, that share high sequence homology. The
subtype sensitivity to activators can be used to distinguish dif-
ferent type activators andmay be related tomolecular determi-
nants that confer the molecular interaction. For example,
retigabine potentiates the homomultimers of all KCNQs
except KCNQ1, whereas ZnPy, in contrast, potentiates all but
KCNQ3. Application of 10 M ztz240 potentiates KCNQ4 and
KCNQ5 more potently than it does KCNQ2, based on the
increase in current amplitude. Nei-
ther KCNQ1 nor KCNQ3 displays
detectable sensitivity to ztz240 (Fig.
4, A and B and Table 1). ztz240
potentiates KCNQ4 and KCNQ5
more potently and with a different
profile compared with KCNQ2.
First, the left shift of activation V1⁄2
by 10 M ztz240 was less for
KCNQ4 and KCNQ5 channels than
for KCNQ2 (KCNQ2 from11.4
4.2 to 58.7  7.7 mV; KCNQ4
from 10.9  1.3 to 27.9  4.4
mV; and KCNQ5 from19.9 2.6
to 31.0  2.3 mV) (Table 1). Sec-
ond, the two-phase deactivation
seen for KCNQ2 was not observed
in KCNQ4 and KCNQ5 channels in
the presence of ztz240. Considering
the different subtype specificity of
ztz240 from that of retigabine or
ZnPy, these data are consistent with
the notion that ztz240 activates
KCNQ channels by a mechanism
different from retigabine and ZnPy.
Efforts to identify key residue(s)
necessary for retigabine sensitivity
(i.e. molecular determinants) have
revealed one conserved tryptophan
in KCNQ2–KCNQ5 that is critical
for retigabine sensitivity. In the case
of KCNQ2, the mutant, W236L, is
functional but no longer sensitive to retigabine (32, 33). How-
ever, KCNQ2(W236L) remains sensitive to ZnPy. Our recent
work revealed that two leucine residues in S5 (Leu249) and
S5-S6 linker (Leu275) of KCNQ2 are key determinants for the
ZnPy-mediated voltage activation curve shift (31). Therefore,
we first tested ztz240 effects on W236L and found that , in the
presence of 10 M ztz240, W236L was potentiated to 1.7 
0.2-fold, similar to that observed with wild-type KCNQ2, 1.9
0.2 (n 3, p 0.05). ztz240 also left-shifted the voltage activa-
tion curve ofW236L significantly, from21.9 1.2 to38.6
7.6 mV (n 4, p	 0.05). Furthermore, its effects on the deac-
tivation persisted and could be better fitted by a biexponential
function, which is also consistentwithwild-typeKCNQ2 (Fig. 4
and Table 2). Similarly, we tested ztz240 effects on L249A,
L275A, and double mutation L249A/L275A, the key determi-
nants for ZnPy sensitivity. As shown in Fig. 4, C and D, and
Table 2, all of the three mutants are sensitive to ztz240. Notice-
ably, all of the threemutants show significant left shifting of the
voltage activation curve after application of ztz240. Taken
together, mutants of the reported residues critical for confer-
ring the sensitivity to either retigabine or ZnPy remain sensitive
to ztz240, providing further evidence that ztz240 acts on or
mediates its effects via different molecular determinants.
To gain further insights into ztz240 effects, simultaneous
application of two different potentiators to KCNQ2was tested.
The rationale is that if both compounds could simultaneously
FIGURE 3. Effects on deactivation by ztz240 on KCNQ2. A, comparison of 10 M ztz240, 10 M ZnPy, and 10
M retigabine (RTG) effects on KCNQ2, in the absence (black) and presence (gray) of drugs. The protocol is
indicated at thebottom.B, histogramshows that ztz240 slows thedeactivationof KCNQ2. Thedeactivationwas
fitted with a biexponential function with fast (f) and slow (s) components. C, the representative traces show
deactivation phases of KCNQ2 channel in the absence (left) or presence of 10 M ztz240 (right). The gray line
indicates 0 pA (base line). The time scale and protocol used are as indicated. D, deactivation phase of KCNQ2
without drugwas fitted by single exponential function, and the time constant () was plotted against different
voltages. E, deactivation of KCNQ2 after application of drugwas fitted by biexponential function, and the time
constants, both f and s, were plotted against different voltages, respectively. F, the normalized activation
phases from the full traces (inset) in the control (black line) and after application of 10M ztz240 (gray line) are
shown. The protocol in Awas used.G, the activation phases in the absence or presence of ztz240were fitted to
a biexponential function, and the time constants (f and s) were plotted against different testing voltages.
H, the dose-response relationship of ztz240 concentration to slow time constant of deactivation (s). The
protocol in Awas used. Error bars, S.E.
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bind to the same channel complex, the net effects are likely to be
non-additive and display unique characteristics. If, however,
one compound has a “dominant” effect by, for example, occu-
pying the site and preventing binding of the second compound,
the resultant current should resemble that when the compound
is applied alone. We first measured the effects of ztz240 in the
presence of 100 M retigabine (saturated concentration). As
shown in Fig. 5A (middle), 100 M retigabine (RTG) increased
outward current (1.1  0.2-fold) and slowed deactivation to
180.6 66.7 ms from 25.8 5.2 ms (n 5). Supplement of 10
M ztz240 further potentiated the outward current (2.0 0.1-
fold), and, more dramatically, it slowed the deactivation (Fig.
5A,middle). The deactivation can only be fitted with two time
constants (Fig. 5D). Different fromztz240 alone, the tail current
persists, displaying a much longer duration up to 40 s (Fig. 5,A,
D, and F). Similarly, combinatorial application of 10 M ZnPy
and ztz240 also showed similar effects (Fig. 5,A–C). A saturated
dose of 30MZnPy was also used in this experiment. However,
it has caused significant instability of recording, due to its tox-
icity (data not shown). The non-additive effects and pro-
nounced prolongation of tail currents observed only in the
presence of the mixed compounds, distinctive from the effects
by individual compounds, indicate that ztz240 can modulate
the same channel complex in combination with either retigab-
ine or ZnPy (Fig. 5, D and F).
Perhaps the most striking effect
of ztz240 on KCNQ channels is the
change of deactivation rate. We
next sought to identify residues crit-
ical for ztz240 effects. The S6 seg-
ment is thought to be involved in
gating modulation of channels. Pre-
vious studies of RL-3 (an activator
for KCNQ1), retigabine, and ZnPy
have identified residues in the S6
segment critical for their effects
(31–33, 37). In addition to the
highly conserved gating hinge gly-
cine (for KCNQ2, this is Gly301) in
voltage-gated potassium channels, a
PVP (proline-valine-proline) or
PAG (for KCNQ2 Pro308-Ala309-
Gly310) bend was proposed as the
“second hinge” of Kv channels (38–
41). We tested whether changing
either proline or alanine of the sec-
ond hinge would cause alteration of
ztz240 effects. The proline 308
mutant resulted in a non-functional
channel. Interestingly, Ala309 mu-
tants to cysteine, valine, and glycine
abolish the current potentiation
(Fig. 6,A and B). These changes also
significantly and differentially af-
fected the deactivation (Fig. 6C).
The slow deactivation time con-
FIGURE 4. The subtype specificity of ztz240 on KCNQ channels. A, whole cell currents of CHO cells transfected
individually with the indicated cDNAs were recorded in the absence (left) and presence (right) of 10 M ztz240. B,
histogramshows10Mztz240potentiationonKCNQ1toKCNQ5.Thenormalizedcurrentamplitudeisshown.C, the
representativetracesofmutantsW236L,L245A,L279A,andL245A/L279Aintheabsence (black) andpresence (gray)
of 10 M ztz240 (left) and corresponding activation curves (right). The representative traces of the mutants were
elicited by depolarization to50mV from the holding potential at120mV. Error bars, S.E.
TABLE 1
ztz240 effects on different KCNQ subtypes
I/I0 indicates the effects of the compounds on the amplitude of outward current of KCNQ channels. I0 is the amplitude of outward current in the absence of the compound.
I is the amplitude of outward current in the presence of the compound. All currents were elicited by 2-s depolarization from80 to50mVwith 10-mV increments from
a holding potential of120 mV. To calculate I/I0, the depolarization was50 mV and was measured at the end of depolarization. To calculate V1⁄2, the tail current elicited
following120 mV was measured. All values are mean S.E. (n 3–6).
I/I0
V1⁄2  deactivation
Control 10 M ztz240 Control 10 M ztz240
mV ms
KCNQ1 0.9 0.0 13.5 1.8 16.6 2.9 32.9 5.2 51.8 5.6
KCNQ2 1.9 0.2 11.4 4.2 58.7 7.7 20.6 3.4 s 3230.5 534.1
f 171.9 62.5
KCNQ3 1.0 0.2 39.8 4.1 43.1 5.4 13.4 2.7 26.0 2.6
KCNQ4 2.4 0.4 10.9 1.3 27.9 4.4 12.2 2.9 15.9 0.9
KCNQ5 3.5 0.4 19.9 2.6 31.0 2.3 7.7 1.1 13.6 3.4a
a p	 0.05.
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stants decreased to 1793.4  319.3 ms for A309C (n  5, p 	
0.05), 1678.9  291.8 ms for A309V (n  7, p 	 0.05), and
4135.6 251.9ms forA309G (n 5). In contrast, this series of
mutants preserved similar sensitivity to retigabine and ZnPy
(Fig. 6A). Taken together, these data revealed one critical
residue that selectively changes ztz240 effects on KCNQ2
channels and are consistent with the notion that ztz240
potentiates KCNQ channels by acting on a new drug-chan-
nel binding site.
Chemical Structures Critical for Slowing the Deactivation—
To examine the SAR of ztz240, we designed and synthesized a
series of analogues with different
and combinatorial replacements on
the two aromatic rings, for a total of
52 compounds, whose activities
were first determined by a Tl-
based assay using a kinetic fluores-
cence reader (see “Experimental
Procedures”) (28). Among them, six
compounds (ztz222, ztz233, ztz239,
ztz245, ztz250, and zls1726; Fig.
7A) were selected. They showed
fluorescence signal increases
equivalent to the positive controls:
10 M retigabine and 10 M ZnPy
(Fig. 7B) displayed concentration-
correlated signal increases (Fig. 7C).
The whole cell patch clamp testing
confirmed that the six compounds
did indeed potentiate the KCNQ2
current (Fig. 7D), with potentiation
ranging from 1.6- to 2.7-fold.
Examination of the Tl assay
results reveals that the amide linker
between the phenyl ring and the
pyridine ring is not tolerant of
change. The nitrogen position in the
heterocyclic ring is also critical for
activity. Only those with nitrogen
located at the 3-position exhibit
pronounced activity. Moreover,
the substitution pattern of fluo-
rine(s) in the phenyl ring plays an
important role. The fluorine(s) at
position 4 and/or 3 is essential for strong activation, whereas
the 2-position deteriorates the effect (see supplemental material).
The unique mode of action conferred by ztz240 is character-
ized by significant, prolonged deactivation and left shifting of
activationV1⁄2; therefore, we used both the time constant of slow
deactivation phase and 
V1⁄2 as parameters to examine the SAR
of the ztz240 analogues. As shown in Fig. 8, switching the fluo-
rine from 4 (ztz240) to 3 (ztz239) resulted in a significant
decrease in the slow time constant, from 3,230.5  534.1 to
1,075.8  44.8 ms (n  3), and of 
V1⁄2 from 42.4  1.2 to
FIGURE5.Non-additiveeffectsonKCNQ2channelusingmixedactivecompounds.A, representative traces
in the absence or presence of drugs are shown as indicated and color-coded. B and C, histograms represent
increase in outward current amplitude (I/I0) in the absence or presence of drugs as indicated. D and E, histo-
grams represent time constants of deactivation in the absence or presence of drugs as indicated. For controls,
RTG and ZnPy, the unfilled bars indicate the time constant revealed by single exponential equation fitting. For
ztz240 alone or ztz240mixedwith RTG or ZnPy, the deactivation could optimally be fittedwith an exponential
equation of two components: fast (filled bars) and slow (unfilled bars) time constants (also see Fig. 3E). F, rep-
resentative traces in the presence of RTG ztz240 (left) and ZnPy ztz240 (right) elicited by the protocol as
indicated. The voltage steps are color-coded as indicated. The dotted lines represent the base line of no current.
Error bars, S.E.
TABLE 2
Themolecular determinants of ztz240 on KCNQ2 channels




Control 10 M ztz240 Control 10 M ztz240
mV ms
KCNQ2 1.9 0.2 12.9 1.2 55.3 1.1 20.6 3.4 s 3,230.5 534.1
f 171.9 62.5
W236L 1.7 0.2 21.9 1.1 38.6 7.6 18.9 1.7 s 835.9 83.3
f 36.2 3.4
L249A 1.8 0.3 7.5 1.5 41.8 2.5 8.6 1.6 s 1103.3 283.4
f 38.4 5.4
L275A 1.8 0.1 3.6 5.4 28.3 3.4 12.2 0.4 s 586.5 60.4
f 26.9 2.5
L249A/L275A 2.3 0.2 7.9 0.9 9.1 1.4 10.5 2.5 s 406.1 14.8
f 14.4 1.8
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24.9  3.8 mV (n  3). After adding back the 4-fluorine
(ztz233), the slow time constantwas restored to 3,074.2 959.5
ms (n 3). These studies demonstrate amore important role of
the 4-fluorine position relative to that of the 3-fluorine posi-
tion, and the 3-fluorine position did not incur a negative effect
on the activity. A similar trend is observed for compounds
ztz250, ztz245, and ztz222, which bear bromine at position
4 instead. These outcomes support the conclusion that fluo-
rine substitution of the phenyl ring contributes to the slow
deactivation. In contrast, it seems that either chlorine or
bromine substitutions (e.g. ztz240 and ztz250) in the pyri-
dine ring are acceptable for conferring the changes in deac-
tivation and left shifting of V1⁄2. The phenomena are also
observed with ztz239 versus ztz245 and with ztz233 versus
ztz222, respectively.
Conversely, we compared two
series of compounds by fixing the
position of either 4-fluorine or 3-
and 4-fluorine on the phenyl ring.
Compound ztz252, without the
chlorine or bromine substituent,
gave rise to only a slight left shift of
V1⁄2 (5.7  2.3 mV) and did not
exhibit slow deactivation (Fig. 9,
left); the overall potentiation of out-
ward current was minimal. A simi-
lar trend is observed with zls1726,
which bears 3- and 4-fluorine but
lacks chlorine or bromine. These
results support the notion that the
chlorine or bromine moiety plays
an important role in mediating
slow deactivation. Hence, the two
modes of potentiation, hypopolariz-
FIGURE 6. Point mutations revealed the critical residue for ztz240 activity. A, the currents of wild type
KCNQ2 and the indicated mutants in the absence or presence of 10 M ztz240, 10 M RTG, and 10 M ZnPy,
respectively. The S6 sequence of KCNQ2 is shown in the inset, and two hinges are highlighted in boldface type.
B, histogram comparing outward current potentiation of A309C, A309V, and A309G with ztz240. C, histogram
comparing deactivation of A309C, A309V, and A309G. Error bars, S.E.
FIGURE 7. Thederivatives of ztz240 activate KCNQ2 channels.A, chemical structure of derivatives of ztz240 and six other derivatives. B, heatmap of Tl flux
assay (F/F0) for the derivatives in duplicate. The Tl
 flux assay is detailed under “Experimental Procedures.” Columns 1 and 2 show controls (buffer, Tl stimulus
solutions, retigabine, ZnPy, and 5337031) for KCNQ2-HEK293 cells, and columns 23 and 24 show controls (buffer, Tl stimulus solutions, retigabine, ZnPy, and
5337031) for wild-type HEK293 cells. C, scatter plot Tl flux assay for the derivatives in two concentrations (2 and 20 M). Black, not active in both concentra-
tions; green, active only in high concentration (20 M); blue, active in both concentrations. F0 and F, fluorescence before and after compound addition,
respectively. D, histograms of whole cell patch clamp currents in the presence of the indicated compounds at 10 M. Error bars, S.E.
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ing shift of V1⁄2 and slowing of deactivation, appear to be con-
tributed by different groups on the compounds.
ztz233 is, in fact, identical to the structure of ICA-27243,
which has been reported for its potent effects on both recom-
binant KCNQ2/3 channels and anti-epileptic activities (12, 14).
The EC50 values for KCNQ2/3were 5.7 0.6M for ztz233 and
6.1 1.2 M for ztz240. This compares well with the reported
EC50 of 4.8  1.6 M for ICA-27243 (14). Their effects on
KCNQ4, under our experimental
protocols, however, were compara-
ble with EC50 values (9.4  4.4 M
for ztz233 and 12.2  1.0 M for
ztz240), similar to that in the earlier
report (14) (Fig. 10). The slowing of
KCNQ2/3 deactivation by ztz240 is
markedly reduced (994.7  178.0
and 71.1  30.1 ms, respectively),
consistent with the lack of effects on
KCNQ3 subunits (Figs. 4 and 10).
DISCUSSION
The physiological roles of KCNQ
channels have provided a clear
rationale for both identification and
pharmacological characterization
of modulatory chemicals, either as a
lead for drug development or as
probes to understand channel gat-
ing mechanisms or functional roles.
Through a screen of 20,000 com-
pounds by Rb flux, we have iso-
lated a number of compounds of
distinct chemotypes. Both the pres-
ent report and our earlier work have
demonstrated that zinc pyrithione
and ztz240 have distinct isoform
specificity. Comparing specific mu-
tant KCNQ2 channels with loss of
sensitivity to zinc pyrithione or reti-
gabine, our results support the
notion that these compounds are
not only representatives of different
chemotypes but also that they rec-
ognize potentially different sites and
act by a uniquemechanismof action
to cause potentiation.
Our screen utilized two different
tracer ions, rubidium and thallium;
both are permeable to most potas-
sium channels. The level of valida-
tion from the primary screen is
around 30%, depending on the tri-
age criteria and hit selection thresh-
old. Among those compounds that
failed to validate, some may have
interesting pharmacology that
would justify further characteriza-
tion. For example, one would pre-
dict that a “potassium” ionophore could also enable the readout
signal, under conditions applied in our screen. But these com-
pounds would probably fail to show channel specificity. The
selection of chemotypes for further characterization was moti-
vated by several factors. Our lead compound 5337031 and its
related structures (Fig. 1A) resulting from our primary screen
with a simple structure have provided a good starting point for
its structural modification to seek more potent KCNQ activa-
FIGURE 8. The roles of fluorine, chlorine, or bromine substitutions in KCNQ activation and deactivation.
The chemical structure of the compounds, as indicated, and the corresponding representative traces in the
absence (black) and presence (gray) of corresponding compounds are shown. The slow time constant (s)
(numbers in italic type) and shifting of V1⁄2 (numbers in normal type) of each compound are as indicated in the
inset. For the recording protocol, see Fig. 3A.
FIGURE 9. The diagram shows the chlorine or bromine substitution is necessary for ztz240 activity on
activation and deactivation of KCNQ2. The chemical structure of the compounds, as indicated, and the
corresponding representative traces in the absence (black) and presence (gray) are shown beside the com-
pound structure. The slowdeactivation time constant (s) (numbers in italic type) and shifting ofV1⁄2 (numbers in
normal type) of each compound are indicated in each inset. NA, not applicable (the compound did not cause
two-phase deactivation). For the recording protocol, see Fig. 3A.
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tors, despite the fact that its structure is similar to that of ICA-
27243. Initially, we decided to replace the “CH” moiety with an
“N” in one of the phenyl rings. The conventional wisdom is that
incorporation of a nitrogen atom can increase the chance of
improving binding affinity to targeted ion channels, due to its
positive charge characteristics. This is seen in several KCNQ
modulators, including, for example, XE991, flupirtine, and reti-
gabine (10). Accordingly, we positioned screening of the nitro-
gen at 2, 3, and 4 to determine the SAR. Moreover, we incor-
porated halogens into the phenyl rings, guided by the Topliss
scheme (34, 35) because halogens
can provide quick SAR information
about electronic and steric effects
on bioactivities. It is noteworthy
that nowadays, it has become gen-
eral practice in drug design to incor-
porate fluorine atom(s) into bioac-
tive molecules to modulate their
biological properties (42). It has
been demonstrated that in many
cases, the substitution of hydrogen
atom(s) with fluorine(s) in a biolog-
ically active molecule improves its
properties, including potency
and/or bioavailability. It is believed
that these effects result from its dis-
tinctive characteristics as the most
electronegative element, including a
highly strong C–F bond and a size
similar to that of the hydrogen
atom. Such effects have been
observed again in current studies of
ztz222, -233, -239, -240, -245, -250,
and -252. Finally, put together, the
studies afford a nice example and an
effective strategy for design and
development of potent and selective
ligand-targeting ion channels.
ztz240 and several related struc-
tures display rather pronounced
effects to slow deactivation.
Although both zinc pyrithione and
retigabine have been known for
their effects of slowing deactivation,
the effect of ztz compounds on
deactivation is far significant. The
experimental results of the pro-
nounced prolongation of tail cur-
rents in Fig. 5 were only observed by
mixed compounds, either ztz240
with retigabine or ztz240 with zinc
pyrithione. This provides compel-
ling evidence suggesting that both
compounds act on the channel to
cause this non-additive effect.
Mutagenesis studies reveal that
Ala309 appears to preferentially af-
fect ztz240 effects (Fig. 6). In addi-
tion, retigabine potentiates all but KCNQ1, whereas zinc pyri-
thione potentiates all KCNQ but KCNQ3. In contrast, ztz240
has subunit specificity for KCNQ2, KCNQ4, and KCNQ5 (Fig.
4). Therefore, the molecular mechanism of the ztz240 effect is
unique, mediated by specific molecular determinants, and
hence consistent with recognizing a new site. However, further
experiments are needed to reach a firm conclusion.
The effect has been seen over a wide range of testing voltages
(Fig. 3), arguing that the in vivo activity of ICA-27243 reported
earlier is due to its effects on KCNQ channels (12). The effects
FIGURE 10. Comparison of ztz233 (ICA-27243) and ztz240 effects on KCNQ2/3 and KCNQ4. A and B, rep-
resentative traces of ztz233 (ICA-27243) and ztz240 effects on KCNQ2/3 heteromultimers, under the same
voltage steps as shown in Fig. 3A. C and D, G-V curve of ztz233 (ICA-27243) and ztz240 on KCNQ2/3 (n 3–6).
The same protocol for wild type KCNQ2 was used in Fig. 2B. E–H, dose-response curves of ztz233 (ICA-27243)
and ztz240 on KCNQ2/3 and KCNQ4 as indicated (n 4–10). Error bars, S.E.
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of these compounds on receptor mediated suppression remain
unknown and require further investigation. Potentiation com-
pounds with minimal effects on voltage-mediated activation
but profound effects on deactivation could be of great interest.
One would predict that these compounds would act under the
voltages that physiologically gate the channels of interest, rem-
iniscent of allosteric modulators for receptors, which function
only after a native ligand engages with the receptor. Thus, a
deliberate search for channel potentiatorswith no or little effect
on gating voltage is of special benefit. Indeed, the high through-
put screening feasibility during the primary screen to specifi-
cally look for compounds affecting deactivation remains a
major obstacle. Nonetheless, one could imagine innovative
approaches by taking advantage of thewealth of structure func-
tion studies, which harbor abundantmutants and data thatmay
be used to profile hits or even to conduct primary screens.
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Addendum—While this manuscript was under review, Padilla et al.
(43) reported that ICA-27243 (ztz233 referenced in this report)
interacts with a site in the voltage-sensitive domain.
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